Suppr超能文献

包膜蛋白 E1 作为西方马脑炎病毒的疫苗靶标。

Envelope protein E1 as vaccine target for western equine encephalitis virus.

机构信息

Defence Research and Development Canada - Suffield, Box 4000, Station Main, Medicine Hat, Alberta T1A 8K6, Canada.

出版信息

Vaccine. 2011 Jan 17;29(4):813-20. doi: 10.1016/j.vaccine.2010.11.009. Epub 2010 Dec 3.

Abstract

Western equine encephalitis virus (WEEV) is a mosquito-borne RNA virus which causes lethal infection in humans and equines. There are no commercial vaccines or anti-WEEV drugs available for humans. We used replication-defective, human adenovirus serotype-5 (HAd5) as a delivery vector for developing WEEV vaccine. Our previous study found delivery of both E1 and E2 envelope proteins of WEEV by HAd5 vector offers complete protection against lethal challenge of WEEV. In this paper, we constructed a HAd5-vectored E1 vaccine, Ad5-E1. Mice given single-dose vaccination of Ad5-E1 were completely protected against both homologous and heterologous WEEV strains. The protection was rapid, which was achieved as early as day 7 after vaccination. In addition, Ad5-E1 induced a strong WEEV-specific T cell response. Our data suggest E1 is a potential target for developing single-dose, fast-acting, HAd5-vectored vaccine for WEEV.

摘要

西方马脑炎病毒(WEEV)是一种由蚊子传播的 RNA 病毒,可导致人类和马类致命感染。目前尚无针对人类的商业疫苗或抗 WEEV 药物。我们使用复制缺陷型人腺病毒血清型 5(HAd5)作为载体来开发 WEEV 疫苗。我们之前的研究发现,HAd5 载体传递 WEEV 的 E1 和 E2 包膜蛋白可提供针对 WEEV 致命性挑战的完全保护。在本文中,我们构建了一种 HAd5 载体 E1 疫苗,Ad5-E1。单次接种 Ad5-E1 的小鼠可完全抵抗同源和异源 WEEV 株的感染。保护作用迅速,早在接种后第 7 天即可实现。此外,Ad5-E1 诱导了强烈的 WEEV 特异性 T 细胞反应。我们的数据表明,E1 是开发用于 WEEV 的单剂量、快速作用、HAd5 载体疫苗的潜在靶标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验